SECAUCUS, N.J., June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report.
The theme of the report, Care Starts Here, reflects the pivotal role Quest plays in an individual's healthcare, providing insights from laboratory diagnostics to drive well-informed decisions. The report details Quest's accomplishments in 2024 across the company's four strategic pillars of corporate responsibility: health access, employee and community engagement, governance and ethics, and environmental sustainability.
"Care runs deep in the Quest culture, energizing our more than 55,000 colleagues to deliver on the Quest Purpose, working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "As this year's report highlights, we created several exciting new innovations and programs in 2024 to improve health quality and access, not only for our patients, but also for our employees and the communities we serve. We look forward to building on this momentum throughout 2025 and beyond."
In 2024, Quest:
To read the full report, click on 2024 Corporate Responsibility Report.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Last Trade: | US$182.83 |
Daily Change: | 3.88 2.17 |
Daily Volume: | 753,944 |
Market Cap: | US$20.440B |
July 29, 2025 July 22, 2025 July 15, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load